NCT06582810 Lidocaine Infusion Treatment for Subarachnoid Hemorrhage Headaches
| NCT ID | NCT06582810 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Kansas Medical Center |
| Condition | Subarachnoid; Hemorrhage, Nontraumatic |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-01-31 |
| Primary Completion | 2027-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2025-01-31 with a primary completion date of 2027-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to evaluate intravenous lidocaine efficacy and safety in treating headache following non-traumatic subarachnoid hemorrhage. Through this prospective analysis, the investigators hope to: 1. show that intravenous lidocaine infusion causes a clinically significant reduction in pain scores in patients with moderate/severe headache pain following non-traumatic subarachnoid hemorrhage; 2. show that intravenous lidocaine infusion is safe in treating headache following non-traumatic subarachnoid hemorrhage; 3. and report vasospasm prevalence in the cohort. Participants will receive lidocaine infusion as treatment for non-traumatic subarachnoid hemorrhage headache and provide pain scores (on a numeric pain scale) every two hours the patients are awake for a maximum of seven days. Monitoring for vasospasm will occur as part of the patients regular medical care.
Eligibility Criteria
Inclusion Criteria: * Patients \> 18 years; * Have a favorable neurological status defined as Hunt and Hess score ≤ 3 (as it accounts for patient awareness); * Can communicate numeric pain scores; * Are diagnosed with non-traumatic subarachnoid hemorrhage Exclusion Criteria: * The patient is diagnosed with traumatic subarachnoid hemorrhage; * If the patient is \< 18 years of age; * If numeric pain scores could not be captured for \> 3 days of hospitalization; * If the patient had a prior aneurysm; * Chronic pain not associated with non-traumatic subarachnoid hemorrhage diagnosis; * A disability before the stroke (\> 2 on modified Rankin Scale score); * A Hunt and Hess score \> 3; * Contraindications to lidocaine (significant cardiac disease, arrhythmia, seizures, previous allergic reaction to lidocaine
Contact & Investigator
Fernando Salgado, MD
PRINCIPAL INVESTIGATOR
University of Kansas Medical Center
Frequently Asked Questions
Who can join the NCT06582810 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Subarachnoid; Hemorrhage, Nontraumatic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06582810 currently recruiting?
Yes, NCT06582810 is actively recruiting participants. Contact the research team at wkrogman@kumc.edu for enrollment information.
Where is the NCT06582810 trial being conducted?
This trial is being conducted at Wichita, United States.
Who is sponsoring the NCT06582810 clinical trial?
NCT06582810 is sponsored by University of Kansas Medical Center. The principal investigator is Fernando Salgado, MD at University of Kansas Medical Center. The trial plans to enroll 20 participants.